IPS HEART has now shown GIVI-MPCs create new human muscle with full length human dystrophin in dystrophic pigs, young and extremely aged Duchenne Muscular Dystrophy (DMD) mice and in a sarcopenia ...

HOUSTON, January 13, 2025--(BUSINESS WIRE)--IPS HEART has been awarded Orphan Drug Designation (ODD) by the FDA for GIVI-MPCs based on its unique ability to create new muscle with full length ...

An Irish woman has launched a fundraiser to help raise money for medical treatment for her seven-year-old son. Una Ennis' son ...

The dysferlin protein is primarily responsible for repairing cell membranes ... successfully removed muscle stem cells from two patients with limb-girdle muscular dystrophy, corrected the genetic ...

Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for ... in patients with muscular dystrophy diseases. The dysferlin protein is primarily ...

Ips Heart Inc. has been awarded orphan drug designation by the FDA for its GIVI-MPC stem cell therapy for Becker muscular dystrophy. GIVI-MPC has the unique ability to create new muscle with full ...

Muscular Dystrophy (MD) is a genetic condition causing progressive muscle weakness and complications in vital organs. Early ...

New partnership hopes to give BSS patients more options for treatment. Viralgen and Axovia Therapeutics are partnering to develop and manufacture a gene therapy for the treatment of retinal dystrophy ...